|
ClinicalTrials.gov identifier | Phase | Status | Study title | Study design |
|
NCT04401423 | II | Completed | TXA127 for the treatment of severe COVID-19 | A double-blind, placebo-controlled randomized trial in hospitalized patients with severe COVID-19 in the United States () [39] |
NCT04605887 | II | Recruiting | Angiotensin 1-7 as a therapy in the treatment of COVID-19 | A placebo-controlled, randomized trial in hospitalized COVID-19 patients with moderate lung disease () [40] |
NCT04778059 | II | Recruiting | Safety and efficacy of USB002 (pharmaceutically formulated Ang-(1-7)) for respiratory distress due to COVID-19 | Placebo-controlled, double-blind, parallel assignment, randomized trial in hospitalized COVID-19 patients in the United States () [41] |
NCT04375124 | Not applicable | Recruiting | Treatment of angiotensin peptide (1-7) for COVID-19 | Open-label, parallel assignment, nonrandomized trial in hospitalized COVID-19 patients in Turkey () [42] |
NCT04633772 | I/II | Recruiting | Use of angiotensin-(1-7) in COVID-19 | Placebo-controlled, double-blind, parallel assignment, randomized trial in hospitalized COVID-19 in Brazil () [43] |
NCT04332666 | II/III | Not yet recruiting | Angiotensin-(1,7) treatment in COVID-19: the ATCO trial | Placebo-controlled, double-blind, parallel assignment, randomized trial in COVID-19 patients with respiratory failure requiring mechanical ventilation in Belgium () [44] |
NCT04570501 | I/II | Not yet recruiting | Angiotensin (1-7) for the treatment of COVID-19 in hospitalized patients | Multicenter, randomized, double-blind, placebo-controlled study in hospitalized COVID-19 patients () [45] |
|